Seres Therapeutics (MCRB) Amortization of Deferred Charges (2014 - 2024)
Seres Therapeutics (MCRB) posted Amortization of Deferred Charges of $463000.0 for Q3 2024, down 4.54% sequentially from $485000.0 in Q2 2024, and up 17.81% YoY from $393000.0 in Q4 2023.
Seres Therapeutics (MCRB) Amortization of Deferred Charges (2014 - 2024) Analysis & Trends
Seres Therapeutics has reported Amortization of Deferred Charges for 9 years, with the latest figure at $463000.0 in Q3 2024.
- Quarterly Amortization of Deferred Charges rose 17.81% year-over-year to $463000.0 in Q3 2024, while the trailing twelve-month figure through Jun 2025 was $463000.0 (down 73.57% YoY) and the FY2024 annual result came in at $1.4 million, up 24.06% from the prior year.
- Amortization of Deferred Charges fell to $463000.0 in Q3 2024 per MCRB's latest filing, from $485000.0 in the prior quarter.
- Over five years, Amortization of Deferred Charges peaked at $2.2 million in Q4 2021 and troughed at -$99000.0 in Q2 2020.
- A 5-year average of $333368.4 and a median of $195000.0 in 2022 frame the typical range for Amortization of Deferred Charges.
- The sharpest annual moves came in 2021 and 2022: Amortization of Deferred Charges jumped 872.07% in 2021, then sank 92.96% in 2022.
- Over 5 years, Amortization of Deferred Charges stood at $222000.0 in 2020, then surged by 872.07% to $2.2 million in 2021, then tumbled by 92.96% to $152000.0 in 2022, then soared by 169.08% to $409000.0 in 2023, then increased by 13.2% to $463000.0 in 2024.
- According to Business Quant data, Amortization of Deferred Charges over the past three periods registered $463000.0, $485000.0, and $465000.0 for Q3 2024, Q2 2024, and Q1 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - |
| 10 | Seres Therapeutics | 43.87 Mn | 43.87 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2024 | 463,000.00 |
| Sep 30, 2024 | 463,000.00 |
| Jun 30, 2024 | 485,000.00 |
| Jun 30, 2024 | 485,000.00 |
| Mar 31, 2024 | 465,000.00 |
| Mar 31, 2024 | 465,000.00 |
| Dec 31, 2023 | 409,000.00 |
| Dec 31, 2023 | 409,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Sep 30, 2023 | 393,000.00 |
| Jun 30, 2023 | 150,000.00 |
| Jun 30, 2023 | 150,000.00 |
| Mar 31, 2023 | 187,000.00 |
| Mar 31, 2023 | 187,000.00 |
| Dec 31, 2022 | 152,000.00 |
| Dec 31, 2022 | 152,000.00 |
| Sep 30, 2022 | 225,000.00 |
| Sep 30, 2022 | 225,000.00 |
| Jun 30, 2022 | 195,000.00 |
| Jun 30, 2022 | 195,000.00 |